NCT06889402View on ClinicalTrials.gov

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Not yet recruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 15, 2025

Study Completion Date

April 30, 2025

Conditions
Esophageal Cancer
Interventions
PROCEDURE

Neoadjuvant therapy with PD-L1 inhibitor

During neoadjuvant treatment, patients may receive neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, or neoadjuvant chemotherapy combined with immunotherapy during the perioperative period.

Trial Locations (1)

100021

Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER